BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Osborn KE, Khan OA, Kresge HA, Bown CW, Liu D, Moore EE, Gifford KA, Acosta LMY, Bell SP, Hohman TJ, Blennow K, Zetterberg H, Jefferson AL. Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition. Alzheimers Dement (Amst) 2019;11:700-9. [PMID: 31700989 DOI: 10.1016/j.dadm.2019.08.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Barker W, Quinonez C, Greig MT, Behar R, Chirinos C, Rodriguez RA, Rosselli M, Rodriguez MJ, Cid RC, Rundek T, McFarland K, Hanson K, Smith G, DeKosky S, Vaillancourt D, Adjouadi M, Marsiske M, Ertekin-Taner N, Golde T, Loewenstein DA, Duara R. Utility of Plasma Neurofilament Light in the 1Florida Alzheimer's Disease Research Center (ADRC). J Alzheimers Dis 2021;79:59-70. [PMID: 33216030 DOI: 10.3233/JAD-200901] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Villa C, Lavitrano M, Salvatore E, Combi R. Molecular and Imaging Biomarkers in Alzheimer's Disease: A Focus on Recent Insights. J Pers Med 2020;10:E61. [PMID: 32664352 DOI: 10.3390/jpm10030061] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Nyberg L, Lundquist A, Nordin Adolfsson A, Andersson M, Zetterberg H, Blennow K, Adolfsson R. Elevated plasma neurofilament light in aging reflects brain white-matter alterations but does not predict cognitive decline or Alzheimer's disease. Alzheimers Dement (Amst) 2020;12:e12050. [PMID: 32587884 DOI: 10.1002/dad2.12050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
4 Thota RN, Chatterjee P, Pedrini S, Hone E, Ferguson JJA, Garg ML, Martins RN. Association of Plasma Neurofilament Light Chain With Glycaemic Control and Insulin Resistance in Middle-Aged Adults. Front Endocrinol 2022;13:915449. [DOI: 10.3389/fendo.2022.915449] [Reference Citation Analysis]
5 Ma W, Zhang J, Xu J, Feng D, Wang X, Zhang F. Elevated Levels of Serum Neurofilament Light Chain Associated with Cognitive Impairment in Vascular Dementia. Dis Markers 2020;2020:6612871. [PMID: 33204362 DOI: 10.1155/2020/6612871] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Bangen KJ, Thomas KR, Weigand AJ, Edmonds EC, Clark AL, Solders S, Delano-Wood L, Galasko DR, Bondi MW; Alzheimer's Disease Neuroimaging Initiative. Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively-defined subtle cognitive decline and MCI. Alzheimers Dement 2021. [PMID: 33860596 DOI: 10.1002/alz.12324] [Reference Citation Analysis]
7 Jiang L, Wang Z, Wang R, Li M, Zhang Y, Yang D. Plasma Neurofilament Light Chain Is Associated with Cognitive Impairment after Posterior Circulation Stroke. Evid Based Complement Alternat Med 2022;2022:2466982. [PMID: 35800005 DOI: 10.1155/2022/2466982] [Reference Citation Analysis]
8 Faldu KG, Shah JS. Alzheimer's disease: a scoping review of biomarker research and development for effective disease diagnosis. Expert Rev Mol Diagn 2022. [PMID: 35855631 DOI: 10.1080/14737159.2022.2104639] [Reference Citation Analysis]
9 O'Bryant S, Petersen M, Hall J, Johnson L, Yaffe K, Braskie M, Toga AW, Rissman RA; HABLE study team. Characterizing plasma NfL in a community-dwelling multi-ethnic cohort: Results from the HABLE study. Alzheimers Dement 2021. [PMID: 34310015 DOI: 10.1002/alz.12404] [Reference Citation Analysis]
10 Tesco G, Lomoio S. Pathophysiology of neurodegenerative diseases: An interplay among axonal transport failure, oxidative stress, and inflammation? Semin Immunol 2022;:101628. [PMID: 35779975 DOI: 10.1016/j.smim.2022.101628] [Reference Citation Analysis]
11 He L, Morley JE, Aggarwal G, Nguyen AD, Vellas B, de Souto Barreto P; MAPT/DSA Group. Plasma neurofilament light chain is associated with cognitive decline in non-dementia older adults. Sci Rep 2021;11:13394. [PMID: 34183688 DOI: 10.1038/s41598-021-91038-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Narayanan S, Shanker A, Khera T, Subramaniam B. Neurofilament light: a narrative review on biomarker utility. Fac Rev 2021;10:46. [PMID: 34131656 DOI: 10.12703/r/10-46] [Reference Citation Analysis]
13 Travica N, Berk M, Marx W. Neurofilament light protein as a biomarker in depression and cognitive function. Curr Opin Psychiatry 2022;35:30-7. [PMID: 34855695 DOI: 10.1097/YCO.0000000000000756] [Reference Citation Analysis]
14 Yuan A, Nixon RA. Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies. Front Neurosci 2021;15:689938. [PMID: 34646114 DOI: 10.3389/fnins.2021.689938] [Reference Citation Analysis]
15 Marks JD, Syrjanen JA, Graff-Radford J, Petersen RC, Machulda MM, Campbell MR, Algeciras-Schimnich A, Lowe V, Knopman DS, Jack CR Jr, Vemuri P, Mielke MM; Alzheimer’s Disease Neuroimaging Initiative. Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. Alzheimers Res Ther 2021;13:199. [PMID: 34906229 DOI: 10.1186/s13195-021-00944-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
16 Zhou B, Fukushima M. Clinical Utility of the Pathogenesis-Related Proteins in Alzheimer's Disease. Int J Mol Sci 2020;21:E8661. [PMID: 33212853 DOI: 10.3390/ijms21228661] [Reference Citation Analysis]
17 Knorr U, Simonsen AH, Jensen CS, Zetterberg H, Blennow K, Akhøj M, Forman J, Hasselbalch SG, Kessing LV. Alzheimer's disease related biomarkers in bipolar disorder - A longitudinal one-year case-control study. J Affect Disord 2022;297:623-33. [PMID: 34728295 DOI: 10.1016/j.jad.2021.10.074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Darmanthé N, Tabatabaei-Jafari H, Cherbuin N; Alzheimer’s Disease Neuroimaging Initiative. Combination of Plasma Neurofilament Light Chain and Mini-Mental State Examination Score Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease within 5 Years. J Alzheimers Dis 2021;82:951-64. [PMID: 34120902 DOI: 10.3233/JAD-210092] [Reference Citation Analysis]